365 related articles for article (PubMed ID: 31673113)
21. Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations.
Pellagatti A; Armstrong RN; Steeples V; Sharma E; Repapi E; Singh S; Sanchi A; Radujkovic A; Horn P; Dolatshad H; Roy S; Broxholme J; Lockstone H; Taylor S; Giagounidis A; Vyas P; Schuh A; Hamblin A; Papaemmanuil E; Killick S; Malcovati L; Hennrich ML; Gavin AC; Ho AD; Luft T; Hellström-Lindberg E; Cazzola M; Smith CWJ; Smith S; Boultwood J
Blood; 2018 Sep; 132(12):1225-1240. PubMed ID: 29930011
[No Abstract] [Full Text] [Related]
22. The Genetics of Myelodysplastic Syndromes: Clinical Relevance.
Chiereghin C; Travaglino E; Zampini M; Saba E; Saitta C; Riva E; Bersanelli M; Della Porta MG
Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440317
[TBL] [Abstract][Full Text] [Related]
23. Impact of chromosome alterations, genetic mutations and clonal hematopoiesis of indeterminate potential (CHIP) on the classification and risk stratification of MDS.
Ganguly BB; Banerjee D; Agarwal MB
Blood Cells Mol Dis; 2018 Mar; 69():90-100. PubMed ID: 29079134
[TBL] [Abstract][Full Text] [Related]
24. Genetics factors associated with myelodysplastic syndromes.
Macedo LC; Silvestre AP; Rodrigues C; de Alencar JB; Zacarias JM; Ambrosio-Albuquerque EP; Sell AM; Visentainer JE
Blood Cells Mol Dis; 2015 Jun; 55(1):76-81. PubMed ID: 25976472
[TBL] [Abstract][Full Text] [Related]
25. A decade of progress in myelodysplastic syndrome with chromosome 5q deletion.
List A; Ebert BL; Fenaux P
Leukemia; 2018 Jul; 32(7):1493-1499. PubMed ID: 29445113
[TBL] [Abstract][Full Text] [Related]
26. Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
Patnaik MM; Lasho TL
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):450-459. PubMed ID: 33275756
[TBL] [Abstract][Full Text] [Related]
27. High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide.
Jonasova A; Bokorova R; Polak J; Vostry M; Kostecka A; Hajkova H; Neuwirtova R; Siskova M; Sponerova D; Cermak J; Mikulenkova D; Cervinek L; Brezinova J; Michalova K; Fuchs O
Eur J Haematol; 2015 Jul; 95(1):27-34. PubMed ID: 25284710
[TBL] [Abstract][Full Text] [Related]
28. Spectrum of complex chromosomal aberrations in a myelodysplastic syndrome and a brief review.
Ganguly BB; Dolai TK; De R; Kadam NN
J Cancer Res Ther; 2016; 12(3):1203-1206. PubMed ID: 28054536
[TBL] [Abstract][Full Text] [Related]
29. Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndrome.
Xu F; Liu L; Chang CK; He Q; Wu LY; Zhang Z; Shi WH; Guo J; Zhu Y; Zhao YS; Gu SC; Fei CM; Li X
Oncotarget; 2016 Feb; 7(7):8119-30. PubMed ID: 26812882
[TBL] [Abstract][Full Text] [Related]
30. Splicing factor mutant myelodysplastic syndromes: Recent advances.
Pellagatti A; Boultwood J
Adv Biol Regul; 2020 Jan; 75():100655. PubMed ID: 31558432
[TBL] [Abstract][Full Text] [Related]
31. Recurrent SRSF2 mutations in MDS affect both splicing and NMD.
Rahman MA; Lin KT; Bradley RK; Abdel-Wahab O; Krainer AR
Genes Dev; 2020 Mar; 34(5-6):413-427. PubMed ID: 32001512
[TBL] [Abstract][Full Text] [Related]
32. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.
Damm F; Kosmider O; Gelsi-Boyer V; Renneville A; Carbuccia N; Hidalgo-Curtis C; Della Valle V; Couronné L; Scourzic L; Chesnais V; Guerci-Bresler A; Slama B; Beyne-Rauzy O; Schmidt-Tanguy A; Stamatoullas-Bastard A; Dreyfus F; Prébet T; de Botton S; Vey N; Morgan MA; Cross NC; Preudhomme C; Birnbaum D; Bernard OA; Fontenay M;
Blood; 2012 Apr; 119(14):3211-8. PubMed ID: 22343920
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms underlying the heterogeneity of myelodysplastic syndromes.
Dussiau C; Fontenay M
Exp Hematol; 2018 Feb; 58():17-26. PubMed ID: 29175473
[TBL] [Abstract][Full Text] [Related]
34. Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.
Giagounidis A; Mufti GJ; Fenaux P; Germing U; List A; MacBeth KJ
Ann Hematol; 2014 Jan; 93(1):1-11. PubMed ID: 24018623
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathologic characterisation of myeloid neoplasms with concurrent spliceosome mutations and myeloproliferative-neoplasm-associated mutations.
Liu YC; Illar GM; Bailey NG
J Clin Pathol; 2020 Nov; 73(11):728-736. PubMed ID: 32217616
[TBL] [Abstract][Full Text] [Related]
36. [Dyserythropoiesis in myelodysplastic syndrome].
Iwama A
Rinsho Ketsueki; 2018; 59(10):2036-2041. PubMed ID: 30305506
[TBL] [Abstract][Full Text] [Related]
37. Impact of splicing factor mutations on clinical features in patients with myelodysplastic syndromes.
Shingai N; Harada Y; Iizuka H; Ogata Y; Doki N; Ohashi K; Hagihara M; Komatsu N; Harada H
Int J Hematol; 2018 Dec; 108(6):598-606. PubMed ID: 30353274
[TBL] [Abstract][Full Text] [Related]
38. The Impact of Epigenetic Modifications in Myeloid Malignancies.
Venney D; Mohd-Sarip A; Mills KI
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34065087
[TBL] [Abstract][Full Text] [Related]
39. Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes.
Fernandez-Mercado M; Burns A; Pellagatti A; Giagounidis A; Germing U; Agirre X; Prosper F; Aul C; Killick S; Wainscoat JS; Schuh A; Boultwood J
Haematologica; 2013 Dec; 98(12):1856-64. PubMed ID: 23831921
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic modifications of splicing factor genes in myelodysplastic syndromes and acute myeloid leukemia.
Wong JJ; Lau KA; Pinello N; Rasko JE
Cancer Sci; 2014 Nov; 105(11):1457-63. PubMed ID: 25220401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]